Thursday, March 1, 2018

C3J Therapeutics Acquires Assets From Synthetic Genomics

Los Angeles-based C3J Therapeutics, a biotech firm developing targeted antimicrobials, and La Jolla-based Synthetic Genomics, said today that C3J has agreed to acquire the engineered bacteriophage assets from Synthetic Genomics. Financial details of the deal were not announced. According to the two, C3J will integrate SGI's proprietary engineered bacteriophage platform into C3J's R&D programs. C3 is focused on developing targeted antimicrobials to create new drugs for combatting antibiotic-resistant bacteria.

---